Gapping up
In reaction to earnings/guidance:
- SKY +4.4%, NTES +4.1%, ZM +3.2%, BBY +2.4%, WOOF +1.9%, AZO +1.7%, ALB +1.2% (increases guidance to relflect lithium contract renegotiations), CRMT +1.1%, CSIQ +0.6%
Other news:
- SWTX +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial )
- ROIV +7.1% (FDA has approved VTAMA (tapinarof) cream)
- OCGN +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart)
- ESEA +3.4% (reinstates dividend first time since 2013; also approves $20 mln share repurchase auth reports earnings)
- SMR +2.2% (signs MOU for first small modular reactor site in Romania)
- BRBR +1.1% (authorizes new $50 mln share repurchase program)
Analyst comments:
- MQ +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)